Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus vaccine + acellular pertussis vaccine
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **diphtheria-tetanus vaccine + acellular pertussis vaccine** (also known as **Tdap** or **dTap**) is a combination vaccine developed by **Changchun Bak Biological Technology** (BCHT) for booster immunization in adolescents and adults aged 10 years and older. This specific formulation is an adsorbed, two-component acellular pertussis vaccine, containing purified pertussis toxoid (PT) and filamentous hemagglutinin (FHA) in combination with diphtheria and tetanus toxoids. The vaccine is adsorbed onto an aluminum-based adjuvant to enhance the immune response. It is designed to prevent diphtheria, tetanus, and pertussis by stimulating the production of protective antibodies through the activation of B and T cells. As of 2024, the vaccine is undergoing Phase II clinical trials in China (e.g., CTR20263005) to evaluate its safety and immunogenicity across different dose levels.
- Other names
- Tdap vaccinedTap vaccineadsorbed acellular pertussis (two-component) combined diphtheria-tetanus vaccineadsorbed acellular pertussis two-component combined diphtheria-tetanus vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria-tetanus vaccine + acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus vaccine + acellular pertussis vaccine.